SHARE NOW
The contract and research organization (CRO) AmplifyBio has announced the acquisition of select assets from privately held biopharmaceutical company PACT Pharma Inc to advance its cell and gene therapy service offerings.
This acquisition will see AmplifyBio gain access to agreed asset purchases of PACT Pharma’s advanced characterization platforms and bioinformatics capabilities, as well as an expert drug development workforce of 40 personnel and PACT’s San Francisco advanced laboratory space, to accelerate innovation across pharmaceutical modalities.
“Our acquisition of these assets from PACT Pharma means that cell and gene therapies can now be differentiated based on safety and efficacy profiles and specific product characteristics, not development processes,” says J. Kelly Ganjei, AmplifyBio CEO and President.
There is currently a lack of consistency in therapeutic characterization, with no single universal process for companies researching, developing, and testing cell and gene therapeutics.
The inconsistency in these discoveries to preclinical testing processes can result in the need for material changes during later developmental stages. Any alterations in therapeutic production can impact manufacturing consistencies and cause safety concerns when it comes to scale-up.
How are you enjoying this news article? Let us know your thoughts, here >>
AmplifyBio’s partnership with PACT Pharma will see them work towards providing an early and consistent characterization of the purity, potency, and viability of treatment throughout its therapeutic development life cycle.
“This deal allows PACT to retain its core intellectual property and continue our mission of developing novel, neoantigen-targeted T-Cell Therapies,” says Scott Garland, PACT Pharma CEO. “At the same time, we’re working with AmplifyBio to leverage our platforms to offer a unique combination of optimization, characterization, safety, and efficacy services to a wider range of clients seeking to better understand the immunology of their adoptive cell therapies,” he adds.
Following the acquisition of PACT’S South San Francisco laboratory under the announced agreement, AmplifyBio also plan to extend its facilities further by building another site in New Albany Ohio.
The proposed 350,000 square feet of multi-functional lab space will provide the Company with the capabilities for complex genotypic and phenotypic characterization analysis in late-stage development.
AmplifyBio has also communicated the expectation to secure future partnerships and developmental platforms to enhance its commercial acceleration to deliver safe, effective, and reproducible cell and gene therapies.
Source: AmplifyBio Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
